Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins

Table 1

Ovarian cancer patient characteristics () and sample characteristics.

(a)

Median age (range)	60 years (41-75)
	Number () of patients (% of all)
Cancer origin
Ovarian	11 (64.7%)
Tubal	3 (17.7%)
Abdominis	2 (11.8%)
Not specified (MB)	1 (5.8%)
FIGO stage
IIIC	7 (41.2%)
IVA	3 (17.7%)
IVB	5 (29.4%)
IV (no substage specified)	1 (5.8%)
No stage (MB)	1 (5.8%)
Histology
High-grade serous	14 (82.4%)
Low-grade serous	1 (5.8%)
Clear cell	1 (5.8%)
MB	1 (5.8%)
Debulking outcome (residual tumor)
Complete (0 cm)	9 (52.9%)
Optimal (<1 cm)	3 (17.7%)
Incomplete (>2 cm)	5 (29.4%)
Vital status (median follow-up 10 months)
Alive	11 (64.7%)
Deceased	6 (35.3%)

(b)

Sample type		Median (range)	CD4/CD8 ratio (range)
Peripheral blood	12	16 (8-27) mL	3.2 (1-6.2)
Ascites	16	738 (217-950) mL	1.0 (0.3-3.6)
Tumor	8	25.1 (2.8-58.0) g	0.6 (0.2-1.6)

Abbreviations: MB: mucinous borderline; FIGO: International Federation of Gynecology and Obstetrics. Two patients also had an additional sarcoma component (in addition to tubal origin and high-grade serous histology).